The new emerging human atypical influenza has been continuously attacked the global public health system for many years. As new human infections, the problem usually occurs. Difficulty in diagnosis and treatment is accepted. Lev and Rager-Zisman [2] noted for “potentially serious risks resulting from misuse” of the new emerging agents including new emerging influenza. Luckily, there has never the verified situation of successful bioterrorism using new atypical influenza. Nevertheless, the risk can be expected. While many new researches and developments are ongoing for drug and vaccine, the data on virus might be further used by bioterrorist for unwanted illegal application. Rebmann et al. [3] noted that “businesses should continue to improve business continuity and pandemic plans to prepare for the next biologic event (ie, pandemic, attack.” To combat a “man made form used for” is the big issue. As noted by Howse, effective laws have to be implemented